Dianthus (DNTH) Therapeutics announced the appointment of John King as Chief Commercial Officer. King brings more than 25 years of global commercial leadership experience within biotechnology, including complement inhibitor experience in neuromuscular and hematological rare diseases. In this newly created position, King will play a critical role in the Company’s corporate and commercial strategy.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential